Glenmark Ponders Partners For Omalizumab And Ryaltris Spray

 
• By Aidan Fry

To help fund Phase III clinical trials and US sales and marketing efforts respectively, Glenmark is looking for partners for both its omalizumab biosimilar candidate and its Ryaltris olopatadine and mometasone combination spray.

Doctor_Handshake
Glenmark is considering whether to bring in partners for two of its key respiratory assets • Source: Shutterstock

More from Biosimilars

More from Products